[Retracted] Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/β-Catenin Signaling Pathway

Table 1

Effects of Afatinib on ORR and DCR in 22 patients.

Systemic tumor response to treatment ()
ORR, % (95% CI)	38.4 (15.2, 59.3)
DCR, % (95% CI)	78.5 (60.8, 97.8)
Complete response, (%)	0 (0.0)
Partial response, (%)	8 (35.7)
Stable disease, (%)	12 (57.4)
Progressive disease, (%)	5 (15.9)

Kaplan-Meier analysis on 22 patients treated with Afatinib and conventional DDP+PEM for the relationship between Afatinib and prognosis, ORR, and DCR in patients with NSCLC.